

Roberto SciagrÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7513137/publications.pdf>

Version: 2024-02-01

107
papers

2,846
citations

201674

27
h-index

189892

50
g-index

110
all docs

110
docs citations

110
times ranked

2977
citing authors

#	ARTICLE	IF	CITATIONS
1	One-tissue compartment model for myocardial perfusion quantification with N-13 ammonia PET provides matching results: A cross-comparison between Carimas, FlowQuant, and PMOD. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2543-2550.	2.1	5
2	Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1946-1951.	2.1	3
3	Myocardial perfusion quantification with Rb-82 PET: good interobserver agreement of Carimas software on global, regional, and segmental levels. <i>Annals of Nuclear Medicine</i> , 2022, 36, 507-514.	2.2	2
4	The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI. <i>Diagnostics</i> , 2022, 12, 844.	2.6	13
5	Appropriateness criteria for the use of cardiac computed tomography, SIC-SIRM part 2: acute chest pain evaluation; stent and coronary artery bypass graft patency evaluation; planning of coronary revascularization and transcatheter valve procedures; cardiomyopathies, electrophysiological applications, cardiac masses, cardio-oncology and pericardial diseases evaluation. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 290-303.	1.5	5
6	EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1040-1069.	6.4	70
7	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	6.4	11
8	The brain connection between stress and heart: a convincing research opportunity to reduce risk and gender disparity in cardiovascular disease. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 433-435.	2.1	3
9	The STREAM trial: Great expectations for getting clearness in an opaque disease. <i>International Journal of Cardiology</i> , 2021, 332, 140-141.	1.7	0
10	SIRM-SIC appropriateness criteria for the use of Cardiac Computed Tomography. Part 1: Congenital heart diseases, primary prevention, risk assessment before surgery, suspected CAD in asymptomatic patients, plaque and epicardial adipose tissue characterization, and functional assessment of stenosis. <i>Radiologia Medica</i> , 2021, 126, 1236-1248.	7.7	18
11	Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms. <i>Nuclear Medicine Communications</i> , 2021, 42, 284-291.	1.1	17
12	Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. <i>Neurological Sciences</i> , 2021, , 1.	1.9	0
13	Sub-endocardial and sub-epicardial measurement of myocardial blood flow using ¹³ NH ₃ PET in man. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1665-1674.	2.1	6
14	Transient ischemic dilation in hypertrophic cardiomyopathy: A complex sign in a complex disease. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 2044-2047.	2.1	0
15	Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. <i>European Journal of Neurology</i> , 2020, 28, 3809-3813.	3.3	9
16	Are disease-related pulmonary perfusion abnormalities detectable in COVID-19 patients? Suspicious findings in a lung perfusion SPECT performed for ruling out classical pulmonary embolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2211-2213.	6.4	4
17	Typical lung carcinoids: review of classification, radiological signs and nuclear imaging findings. <i>Clinical and Translational Imaging</i> , 2020, 8, 79-94.	2.1	2
18	Novel 3D heart left ventricle muscle segmentation method for PET-gated protocol and its verification. <i>Annals of Nuclear Medicine</i> , 2019, 33, 629-638.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Characterization of functionally significant coronary artery disease by a coronary computed tomography angiography-based index: a comparison with positron emission tomography. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 897-905.	1.2	18
20	EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras. <i>European Journal of Hybrid Imaging</i> , 2019, 3, 11.	1.5	46
21	Microvascular Dysfunction in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2019, 12, 1.	0.6	0
22	Right ventricular perfusion: Do we need additional evidence or just a simple methodology?. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 272-274.	2.1	2
23	Comparison between the summed difference score and myocardial blood flow measured by ¹³ N-ammonia. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 1621-1628.	2.1	21
24	Prediction of functional recovery after primary PCI using the estimate of myocardial salvage in gated SPECT early after acute myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 530-537.	6.4	11
25	Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a ¹³ NH ₃ gated PET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 866-875.	6.4	29
26	Systematic review of cost-effectiveness of myocardial perfusion scintigraphy in patients with ischaemic heart disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 825-832.	1.2	15
27	A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1073-1089.	1.2	74
28	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2413-2422.	6.4	20
29	Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2423-2432.	6.4	80
30	Segmental quantitative myocardial perfusion with PET for the detection of significant coronary artery disease in patients with stable angina. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1522-1529.	6.4	18
31	Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1530-1545.	6.4	44
32	Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 780-792.	6.4	195
33	COmparison between COronary THrombus aspiration with Angiojet® or Export® catheter in patients with ST-elevation myocardial infarction submitted to primary angioplasty: The COCOTH Study. <i>International Journal of Cardiology</i> , 2016, 203, 757-762.	1.7	9
34	Interventricular septum metastasis in neuroendocrine tumour. <i>Endocrine</i> , 2016, 53, 870-871.	2.3	0
35	Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 60, 354-61.	0.7	6
36	Effect of diabetes on scintigraphic infarct size in STEMI patients undergoing primary angioplasty. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 322-328.	4.0	7

#	ARTICLE	IF	CITATIONS
37	Validation of pixel-wise parametric mapping of myocardial blood flow with $^{13}\text{NH}_3$ PET in patients with hypertrophic cardiomyopathy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1581-1588.	6.4	12
38	Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. <i>International Journal of Cardiology</i> , 2015, 197, 147-153.	1.7	23
39	Smoking and infarct size among STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2014, 233, 145-148.	0.8	7
40	Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2014, 234, 244-248.	0.8	6
41	Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 81-86.	2.1	13
42	Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. <i>European Heart Journal</i> , 2014, 35, 184-191.	2.2	102
43	Quantification of Myocardial Blood Flow in Absolute Terms Using ^{82}Rb PET Imaging. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1119-1127.	5.3	144
44	Effects of a timely therapy with doxycycline on the left ventricular remodeling according to the pre-procedural TIMI flow grade in patients with ST-elevation acute myocardial infarction. <i>Basic Research in Cardiology</i> , 2014, 109, 412.	5.9	13
45	SPECT and PET Protocols for Imaging Myocardial Viability. <i>Current Cardiovascular Imaging Reports</i> , 2014, 7, 1.	0.6	5
46	Surgical Correction of Left Coronary Artery Origin From the Right Coronary Artery. <i>Annals of Thoracic Surgery</i> , 2013, 95, e1-e2.	1.3	5
47	Preinfarction angina does not affect infarct size in STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2013, 226, 153-156.	0.8	9
48	Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty. <i>International Journal of Cardiology</i> , 2013, 167, 1508-1513.	1.7	16
49	Relation of Gender to Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. <i>American Journal of Cardiology</i> , 2013, 111, 936-940.	1.6	25
50	Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 542-547.	6.4	3
51	Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty. <i>Journal of Hypertension</i> , 2013, 31, 2433-2437.	0.5	5
52	Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. <i>European Journal of Heart Failure</i> , 2013, 15, 1363-1373.	7.1	49
53	SBP ratio in exercise stress testing. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 714-718.	1.5	0
54	Quantitative Cardiac Positron Emission Tomography: The Time Is Coming!. <i>Scientifica</i> , 2012, 2012, 1-16.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations. <i>Journal of the American College of Cardiology</i> , 2011, 58, 839-848.	2.8	138
56	Prognostic implications of post-stress ejection fraction decrease detected by gated SPECT in the absence of stress-induced perfusion abnormalities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 485-490.	6.4	21
57	Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1124-1131.	6.4	27
58	Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 12-22.	6.4	2
59	Reliability of myocardial perfusion gated SPECT for the reproducible evaluation of resting left ventricular functional parameters in long-term follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1722-1729.	6.4	8
60	Evaluation of the influence of age and gender on the relationships between infarct size, infarct severity, and left ventricular ejection fraction in patients successfully treated with primary percutaneous coronary intervention. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 444-449.	2.1	5
61	Feasibility of an accurate assessment of myocardial salvage by comparing functional and perfusion abnormalities in post-reperfusion gated SPECT. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 825-830.	2.1	7
62	Abnormal response to mental stress in patients with Takotsubo cardiomyopathy detected by gated single photon emission computed tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 765-772.	6.4	13
63	Redefining the Success of Mechanical Reperfusion. , 2010, , 234-239.		0
64	Microvascular Dysfunction, Myocardial Ischemia, and Progression to Heart Failure in Patients with Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 452-461.	2.4	53
65	Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2009, 16, 92-96.	2.1	25
66	Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischARGE gated SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 906-911.	6.4	12
67	Is 16-frame really superior to 8-frame gated SPECT for the assessment of left ventricular volumes and ejection fraction? Comparison of two simultaneously acquired gated SPECT studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2059-2065.	6.4	18
68	Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 644-654.	2.1	4
69	Assessment of the Influence of Atrial Fibrillation on Gated SPECT Perfusion Data by Comparison with Simultaneously Acquired Nongated SPECT Data. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1283-1287.	5.0	4
70	Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1090-1096.	5.0	68
71	Influence of the postexercise acquisition delay on the detection of functional abnormalities in sestamibi-gated SPECT. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 334-340.	2.1	7
72	The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1107-1122.	6.4	26

#	ARTICLE	IF	CITATIONS
73	Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. <i>American Heart Journal</i> , 2006, 152, 1133-1139.	2.7	30
74	ST-Segment Analysis to Predict Infarct Size and Functional Outcome in Acute Myocardial Infarction Treated With Primary Coronary Intervention and Adjunctive Abciximab Therapy. <i>American Journal of Cardiology</i> , 2006, 97, 48-54.	1.6	28
75	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2005, 9, 307-308.	0.0	0
76	A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. <i>American Heart Journal</i> , 2005, 150, 220.e1-220.e5.	2.7	18
77	Gated SPECT evaluation of outcome after abciximab-supported primary infarct artery stenting for acute myocardial infarction: the scintigraphic data of the abciximab and carbostent evaluation (ACE) randomized trial. <i>Journal of Nuclear Medicine</i> , 2005, 46, 722-7.	5.0	10
78	Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 93, 1033-1035.	1.6	160
79	Relationship of infarct size and severity versus left ventricular ejection fraction and volumes obtained from 99mTc-sestamibi gated single-photon emission computed tomography in patients treated with primary percutaneous coronary intervention. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 969-74.	6.4	35
80	Use of 99mTc-sestamibi gated SPECT to assess the influence of anterograde flow before primary coronary angioplasty on tissue salvage and functional recovery in acute myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1378-85.	6.4	6
81	Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. <i>Journal of Nuclear Medicine</i> , 2004, 45, 164-8.	5.0	51
82	Usefulness of dobutamine Tc-99m sestamibi-gated single-photon emission computed tomography for prediction of left ventricular ejection fraction outcome after coronary revascularization for ischemic cardiomyopathy. <i>American Journal of Cardiology</i> , 2002, 89, 817-821.	1.6	27
83	Predicting revascularization outcome in patients with coronary artery disease and left ventricular dysfunction (data from the SEMINATOR study). <i>American Journal of Cardiology</i> , 2002, 89, 1369-1373.	1.6	15
84	Low-dose dobutamine nitrate-enhanced technetium 99m sestamibi gated SPECT versus low-dose dobutamine echocardiography for detecting reversible dysfunction in ischemic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2002, 9, 402-406.	2.1	25
85	Comparison of dobutamine echocardiography and 99mTc-sestamibi tomography for prediction of left ventricular ejection fraction outcome after acute myocardial infarction treated with successful primary coronary angioplasty. <i>Journal of Nuclear Medicine</i> , 2002, 43, 8-14.	5.0	83
86	Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in patients with chronic coronary artery disease and left ventricular dysfunction: comparison between baseline and nitrate-enhanced imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 680-687.	2.1	27
87	Usefulness of distinct activity thresholds according to baseline regional asynergy for predicting functional recovery in patients with chronic coronary artery disease and left ventricular dysfunction: A study with nitrate-enhanced sestamibi gated SPECT. <i>Journal of Nuclear Cardiology</i> , 2001, 8, 555-560.	2.1	5
88	Prediction of functional recovery in patients with chronic coronary artery disease and left ventricular dysfunction combining the evaluation of myocardial perfusion and of contractile reserve using nitrate-enhanced technetium-99m sestamibi gated single-photon emission computed tomography and Dobutamine stress. <i>American Journal of Cardiology</i> , 2001, 87, 1346-1350.	1.6	27
89	Comparison of baseline and low-dose dobutamine technetium-99m sestamibi scintigraphy with low-dose dobutamine echocardiography for predicting functional recovery after revascularization. <i>American Journal of Cardiology</i> , 2000, 86, 153-157.	1.6	14
90	Nitrate-enhanced gated technetium 99m sestamibi SPECT for evaluating regional wall motion at baseline and during low-dose dobutamine infusion in patients with chronic coronary artery disease and left ventricular dysfunction: Comparison with two-dimensional echocardiography. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 426-431.	2.1	30

#	ARTICLE	IF	CITATIONS
91	Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. Journal of the American College of Cardiology, 2000, 36, 739-745.	2.8	69
92	Technetium-99m-labeled perfusion tracers for the detection of myocardial viability. Developments in Cardiovascular Medicine, 2000, , 91-112.	0.1	0
93	Head-to-head comparison of exercise stress testing, pharmacologic stress echocardiography, and perfusion tomography as first-line examination for chest pain in patients without history of coronary artery disease. Journal of Nuclear Cardiology, 1998, 5, 19-27.	2.1	58
94	Prediction of post-revascularization functional recovery of asynergic myocardium using quantitative thallium-201 rest-redistribution tomography: has the reverse redistribution pattern an independent significance?. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 594-600.	6.4	3
95	Detection of Malignant Thymoma During Myocardial Perfusion Tomography With Tc-99m Sestamibi. Clinical Nuclear Medicine, 1998, 23, 842-843.	1.3	4
96	Comparison of Baselineâ€“Nitrate Technetium-99m Sestamibi With Restâ€“Redistribution Thallium-201 Tomography in Detecting Viable Hibernating Myocardium and Predicting Postrevascularization Recovery. Journal of the American College of Cardiology, 1997, 30, 384-391.	2.8	109
97	Alternative Approaches to the Prognostic Stratification of Mild to Moderate Primary Vesicoureteral Reflux in Children. Journal of Urology, 1996, 155, 2052-2056.	0.4	14
98	Influence of the assessment of defect severity and intravenous nitrate administration during tracer injection on the detection of viable hibernating myocardium with data-based quantitative technetium 99m-labeled sestamibi single-photon emission computed tomography. Journal of Nuclear Cardiology, 1996, 3, 221-230.	2.1	26
99	201Tl and 99mTc-labeled sestamibi for assessment of myocardial viability. Journal of Nuclear Cardiology, 1996, 3, 453.	2.1	0
100	Renal and Limb Vasodilatation during Acute Betaâ€“Adrenoceptor Blockade with Indenolol. Journal of Clinical Pharmacology, 1995, 35, 176-181.	2.0	1
101	Rest technetium-99m sestmibi temography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. Journal of the American College of Cardiology, 1994, 24, 1282-1289.	2.8	110
102	Infarct-avid scintigraphy with technetium-99m-pyrophosphate. Coronary Artery Disease, 1992, 3, 1073-1080.	0.7	0
103	Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: Comparison with thallium-201 myocardial scintigraphy. American Heart Journal, 1991, 122, 1609-1616.	2.7	71
104	Comparison of tomographic and planar imaging for the evaluation of thrombolytic therapy in acute myocardial infarction using pre- and post-treatment myocardial scintigraphy with technetium-99m sestamibi. American Heart Journal, 1991, 122, 13-22.	2.7	8
105	Assessment of ventricular function with first-pass radionuclide angiography using technetium 99m hexakis-2-methoxyisobutylisonitrile: a European multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 178-183.	2.1	19
106	Single photon emission computed tomography with technetium-99m hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before and after thrombolytic treatment: Assessment of salvaged myocardium and prediction of late functional recovery. Journal of the American College of Cardiology, 1990, 15, 301-314.	2.8	110
107	Treatment of Hypertensive Emergencies. Journal of Cardiovascular Pharmacology, 1986, 8, S46-S50.	1.9	6